Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tang caopian (唐草片) is a Traditional Chinese Medicine (TCM) formulation approved by the National Medical Products Administration (NMPA) of China for the treatment of HIV/AIDS. Developed by the Henan Institute of Traditional Chinese Medicine and manufactured by Beijing Winsunny Pharmaceutical, it is a multi-herb tablet designed to enhance immune function and inhibit viral replication. The drug is primarily indicated for asymptomatic HIV-infected individuals or those in the early stages of the disease, with the goal of maintaining CD4+ T-lymphocyte counts, reducing viral load, and delaying the progression to AIDS. It has been evaluated in various clinical trials, including Phase 1 and Phase 2 studies, to assess its safety and efficacy as a monotherapy or in combination with other treatments. It was the first TCM specifically approved in China for HIV/AIDS treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tang caopian.